A case of hemolytic disease of the fetus and newborn caused by anti-Jk3 and its clinical features
10.13303/j.cjbt.issn.1004-549x.2026.02.014
- VernacularTitle:一例抗-Jk3引起胎儿新生儿溶血病及其临床特征
- Author:
Heng YANG
1
;
Suying HE
1
Author Information
1. Department of Blood Transfusion, Zhujiang Hospital, Southern Medical University, Guangzhou 510080, China
- Publication Type:Journal Article
- Keywords:
anti-Jk3;
Jk (a-b-);
Kidd blood group system;
hemolytic disease of the fetus and newborn (HDFN)
- From:
Chinese Journal of Blood Transfusion
2026;39(2):256-260
- CountryChina
- Language:Chinese
-
Abstract:
Objective: To analyze a case of hemolytic disease of the fetus and newborn (HDFN) caused by anti-Jk3 antibody, which was induced in a rare Jk (a-b-) blood type resulting from a gene mutation in the Kidd blood group system, so as to provide a reference for the diagnosis and treatment of HDFN associated with this antibody. Methods: HDFN-related blood group serological testing, antibody identification and specific blood group antigen identification were performed on blood samples from the infant and the mother. The mother's Kidd blood group was analyzed by molecular biology methods. Clinical data of the infant and the mother were collected, and changes in bilirubin, hemoglobin (Hb), and other results during the disease progression of the infant were analyzed. Results: The infant was blood type B, Rh (D) positive, and Kidd blood group Jk (a-b+). The mother was blood type O, Rh (D) positive. Due to an IVS5-1 G>A mutation, the mother exhibited a Jk (a-b-) phenotype. Anti-Jk3 antibodies were detected in the mother's plasma. The infant was diagnosed with HDFN due to anti-Jk3. During treatment, the total bilirubin (TBil) and indirect bilirubin (IBil) levels of the infant initially increased and then decreased, with peak monitored values of 228.2 μmol/L and 208.9 μmol/L, respectively. Hb decreased from 180 g/L at birth to 93 g/L. After phototherapy and symptomatic treatment, the infant's indicators stabilized, and the general condition improved. The infant was discharged after recovery. Conclusion: Clinically, HDFN caused by anti-Jk3 antibodies is relatively rare. For HDFN induced by this antibody, early detection, intervention, and treatment are essential to address the transfusion challenges posed by the extreme scarcity of Jk3-negative blood sources, thereby minimizing adverse outcomes in affected infants to the greatest extent possible.
